Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.61 |
| ▸ | PNMT | P11086 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327075 | 1.00 | CD44 (0.61) | CD44PNMTMAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1124513 | 0.98 | CD44 (0.59) | CD44PNMTMAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29586475 | 0.98 | CD44 (0.59) | CD44PNMTMAOBDRD2DRD3 | |
| SCHEMBL3052029 | 0.84 | PNMT (0.61) | CD44PNMTMAOBHTR2CPRCP | |
| Hydrochloric Acid SCHEMBL2258194 | 0.82 | PNMT (0.59) | CD44PNMTMAOBHTR2CPRCP | |
| SCHEMBL330078 | 0.81 | CD44 (0.42) | CD44PNMTMAOBDRD2DRD3 | |
| SCHEMBL29972587 | 0.81 | CD44 (0.42) | CD44PNMTMAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL621622 | 0.79 | CD44 (0.41) | CD44PNMTMAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL30453968 | 0.79 | CD44 (0.41) | CD44PNMTMAOBDRD2DRD3 | |
| SCHEMBL14692360 | 0.77 | PNMT (0.50) | CD44PNMTMAOBHTR2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022174083-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-109863145-B | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | CD44 958/4885PNMT 2800/4885MAOB 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.